By the end of this session, attendees will be able to:

• Understand the potential storage requirements for autologous and allogeneic therapies and associated materials
• Recognize the challenges to scaling the advanced therapy supply chain
• Describe the differences between small molecule / biologics and advanced therapy supply chains